

Srdan Verstovsek,, of Medicine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5704075/publications.pdf>

Version: 2024-02-01

320
papers

21,032
citations

13865

67
h-index

11939

134
g-index

325
all docs

325
docs citations

325
times ranked

10789
citing authors

#	ARTICLE	IF	CITATIONS
1	Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. <i>Haematologica</i> , 2022, 107, 1599-1607.	3.5	27
2	Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline "chemotherapy-free"™ therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 672-675.	1.3	2
3	Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. <i>Annals of Hematology</i> , 2022, 101, 131-137.	1.8	20
4	Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. <i>Leukemia and Lymphoma</i> , 2022, 63, 694-702.	1.3	22
5	SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 210-223.	0.4	9
6	Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes. <i>Acta Haematologica</i> , 2022, 145, 448-453.	1.4	4
7	Momelotinib: an emerging treatment for myelofibrosis patients with anemia. <i>Journal of Hematology and Oncology</i> , 2022, 15, 7.	17.0	36
8	Improved survival of patients with myelofibrosis in the last decade: Single-center experience. <i>Cancer</i> , 2022, , .	4.1	16
9	Disease Modification in Myelofibrosis: An Elusive Goal?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1147-1154.	1.6	12
10	Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. <i>Blood Cancer Journal</i> , 2022, 12, 23.	6.2	4
11	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. <i>International Review of Cell and Molecular Biology</i> , 2022, 366, 83-124.	3.2	12
12	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. <i>Journal of Clinical Oncology</i> , 2022, 40, 1671-1680.	1.6	60
13	Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis. <i>Scientific Reports</i> , 2022, 12, 4674.	3.3	2
14	Managing patients with myelofibrosis and thrombocytopenia. <i>Expert Review of Hematology</i> , 2022, , 1-9.	2.2	2
15	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. <i>Hematological Oncology</i> , 2022, 40, 491-504.	1.7	0
16	Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. <i>Leukemia Research</i> , 2022, 115, 106809.	0.8	15
17	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. <i>British Journal of Haematology</i> , 2022, 198, 317-327.	2.5	18
18	Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. <i>Lancet Haematology</i> , 2022, 9, e434-e444.	4.6	18

#	ARTICLE	IF	CITATIONS
19	GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	7
20	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	7.2	1,211
21	STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. <i>Journal of Immunology</i> , 2022, 208, 2847-2855.	0.8	6
22	Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT) study. <i>British Journal of Haematology</i> , 2022, 198, 1065-1068.	2.5	4
23	Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update. <i>Cancers</i> , 2022, 14, 3474.	3.7	9
24	Impact of SF3B1 mutation in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2022, 63, 2701-2705.	1.3	2
25	Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 224-229.	0.4	4
26	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 909-917.	1.3	11
27	Accelerated Phase of Myeloproliferative Neoplasms. <i>Acta Haematologica</i> , 2021, 144, 484-499.	1.4	26
28	Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era. <i>Leukemia and Lymphoma</i> , 2021, 62, 2253-2260.	1.3	5
29	Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. <i>British Journal of Haematology</i> , 2021, 193, 1004-1008.	2.5	8
30	Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. <i>Blood Advances</i> , 2021, 5, 2156-2164.	5.2	33
31	Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 409-429.	2.2	3
32	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. <i>HemaSphere</i> , 2021, 5, e562.	2.7	20
33	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. <i>Future Oncology</i> , 2021, 17, 1449-1458.	2.4	31
34	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	5.2	56
35	Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7046-7046.	1.6	2
36	Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 318-327.e6.	0.4	11

#	ARTICLE	IF	CITATIONS
37	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer Journal, 2021, 11, 98.	6.2	24
38	BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).. Journal of Clinical Oncology, 2021, 39, TPS7057-TPS7057.	1.6	7
39	Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy. Journal of Immunotherapy and Precision Oncology, 2021, 4, 117-128.	1.4	6
40	SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 641-649.	0.4	11
41	Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Advances, 2021, 5, 3163-3173.	5.2	17
42	Avapritinib for Systemic Mastocytosis. Expert Review of Hematology, 2021, 14, 687-696.	2.2	17
43	Phase II study of single-agent nivolumab in patients with myelofibrosis. Annals of Hematology, 2021, 100, 2957-2960.	1.8	11
44	Potential New Therapeutic Approaches for Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S130-S133.	0.4	0
45	Poster: MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S231.	0.4	1
46	Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia, 2021, 35, 3361-3363.	7.2	12
47	Real-World Patient Characteristics and Treatment Patterns of Ruxolitinib Among Patients With Advanced Essential Thrombocythemia at Community Clinical Practice. Leukemia Research, 2021, 110, 106711.	0.8	1
48	Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data. Blood, 2021, 138, 2568-2568.	1.4	8
49	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	5.5	9
50	Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial. Blood, 2021, 138, 141-141.	1.4	16
51	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine, 2021, 27, 2183-2191.	30.7	78
52	Mutational profiling in myelofibrosis: implications for management. International Journal of Hematology, 2020, 111, 192-199.	1.6	9
53	Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia, 2020, 34, 799-810.	7.2	58
54	Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers, 2020, 12, 2891.	3.7	13

#	ARTICLE	IF	CITATIONS
55	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. <i>Blood Advances</i> , 2020, 4, 4282-4291.	5.2	77
56	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	4.6	201
57	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e10-e13.	2.5	2
58	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. <i>Cancer</i> , 2020, 126, 4322-4331.	4.1	19
59	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
60	Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. <i>Haematologica</i> , 2020, 106, haematol.2020.249441.	3.5	2
61	Givinostat: an emerging treatment for polycythemia vera. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 525-536.	4.1	32
62	JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. <i>HemaSphere</i> , 2020, 4, e424.	2.7	49
63	Outcome of patients with IDH1/2-mutated post-acute myeloid leukemia (AML) in the era of IDH inhibitors. <i>Blood Advances</i> , 2020, 4, 5336-5342.	5.2	37
64	New Therapies in Development for Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S69-S71.	0.4	1
65	MPN-148: Momelotinib Dose-Intensity is Maintained in JAK Inhibitor-Naïve and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S330.	0.4	1
66	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1439-1445.	2.0	17
67	Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. <i>Annals of Hematology</i> , 2020, 99, 2555-2564.	1.8	8
68	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
69	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTAS2 study using stringent criteria for ruxolitinib failure. <i>American Journal of Hematology</i> , 2020, 95, 594-603.	4.1	96
70	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	7.2	37
71	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e226-e237.	4.6	93
72	Clinical value of event-free survival in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1690-1699.	5.2	4

#	ARTICLE	IF	CITATIONS
73	The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 415-421.	0.4	38
74	Mechanistic basis and efficacy of targeting the β -catenin/TCF7L2/JMJD6/c-Myc axis to overcome resistance to BET inhibitors. <i>Blood</i> , 2020, 135, 1255-1269.	1.4	27
75	Management of myelofibrosis after ruxolitinib failure. <i>Leukemia and Lymphoma</i> , 2020, 61, 1797-1809.	1.3	13
76	Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients. <i>Blood</i> , 2020, 136, 51-52.	1.4	12
77	The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2020, 136, 49-50.	1.4	21
78	Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study. <i>Blood</i> , 2020, 136, 47-48.	1.4	24
79	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. <i>Blood</i> , 2020, 136, 39-40.	1.4	10
80	Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis. <i>Blood</i> , 2020, 136, 18-19.	1.4	5
81	The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 Å– 109/L to < 100 Å– 109/L) at Baseline. <i>Blood</i> , 2020, 136, 4-5.	1.4	6
82	Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval. <i>Blood</i> , 2020, 136, 46-47.	1.4	6
83	Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. <i>Blood Advances</i> , 2020, 4, 5929-5935.	5.2	9
84	Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitolax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy. <i>Blood</i> , 2020, 136, 15-16.	1.4	3
85	Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia. <i>Blood</i> , 2020, 136, 43-44.	1.4	6
86	Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States. <i>Blood</i> , 2020, 136, 12-13.	1.4	1
87	Improved Survival of Patients with Myelofibrosis in the Last Decade. <i>Blood</i> , 2020, 136, 50-51.	1.4	2
88	Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. <i>British Journal of Haematology</i> , 2019, 185, 382-386.	2.5	6
89	Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 460-468.	2.3	14
90	Updates in the management of polycythemia vera and essential thrombocythemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071987005.	2.5	25

#	ARTICLE	IF	CITATIONS
91	Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS ONE, 2019, 14, e0222912.	2.5	8
92	New Concepts of Treatment for Patients with Myelofibrosis. Current Treatment Options in Oncology, 2019, 20, 5.	3.0	12
93	The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2019, 14, 310-327.	2.3	21
94	Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Annals of Hematology, 2019, 98, 1611-1616.	1.8	15
95	Emerging drugs for essential thrombocythemia. Expert Opinion on Emerging Drugs, 2019, 24, 93-105.	2.4	2
96	SOHO State of the Art Updates and Next Questions: Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 191-199.	0.4	1
97	<scp>SMAC</scp> mimetics as potential cancer therapeutics in myeloid malignancies. British Journal of Haematology, 2019, 185, 219-231.	2.5	29
98	Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood, 2019, 133, 2348-2351.	1.4	43
99	Myelofibrosis osteoclasts are clonal and functionally impaired. Blood, 2019, 133, 2320-2324.	1.4	13
100	Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer, 2019, 125, 1855-1866.	4.1	21
101	A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Advances, 2019, 3, 2264-2271.	5.2	17
102	Targeting nuclear β -catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia, 2019, 33, 1373-1386.	7.2	32
103	Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare <i>JAK2</i> Exon 12 <i>e14a3 (b3a3) BCR/ABL Fusion Transcript</i>. Acta Haematologica, 2019, 141, 23-27.	1.4	6
104	A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1767-1774.	1.3	20
105	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. Blood, 2019, 134, 557-557.	1.4	54
106	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood, 2019, 134, 670-670.	1.4	42
107	The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden. Blood, 2019, 134, 1674-1674.	1.4	6
108	Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood, 2019, 134, 4163-4163.	1.4	25

#	ARTICLE	IF	CITATIONS
109	Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count $\leq 50,000/\text{mL}$). <i>Blood</i> , 2019, 134, 4175-4175.	1.4	15
110	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 668-668.	1.4	16
111	Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. <i>Blood</i> , 2019, 134, 555-555.	1.4	17
112	Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis. <i>Blood</i> , 2019, 134, 4178-4178.	1.4	4
113	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2019, 134, 558-558.	1.4	19
114	Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7059-7059.	1.6	9
115	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. <i>JAMA Oncology</i> , 2018, 4, 652.	7.1	261
116	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	7.2	415
117	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e73-e81.	4.6	211
118	Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Hematology and Oncology</i> , 2018, 11, 42.	17.0	63
119	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. <i>Annals of Hematology</i> , 2018, 97, 1183-1191.	1.8	12
120	Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. <i>European Journal of Haematology</i> , 2018, 100, 257-263.	2.2	40
121	SOHO State-of-the-Art Update and Next Questions: MPN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 1-12.	0.4	7
122	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 277-285.	4.1	54
123	Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2018, 97, 109-121.	1.8	27
124	Mutational landscape of myelodysplastic/myeloproliferative neoplasm "unclassifiable". <i>Blood</i> , 2018, 132, 2100-2103.	1.4	40
125	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , 2018, 132, 1664-1674.	1.4	62
126	Management of Myelofibrosis-Related Cytopenias. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 164-172.	2.3	20

#	ARTICLE	IF	CITATIONS
127	The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2018, 97, 2071-2080.	1.8	32
128	Sustained release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis. <i>Hematological Oncology</i> , 2018, 36, 701-708.	1.7	6
129	Kit Mutations. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 411-428.	1.9	15
130	A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3K β Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 353-353.	1.4	13
131	Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients. <i>Blood</i> , 2018, 132, 4282-4282.	1.4	7
132	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. <i>Blood</i> , 2018, 132, 686-686.	1.4	44
133	LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. <i>Blood</i> , 2018, 132, 687-687.	1.4	14
134	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2017, 389, 612-620.	13.7	95
135	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. <i>Haematologica</i> , 2017, 102, 327-335.	3.5	87
136	A phase 2 study of simtuzumab in patients with primary, post \leq polycythaemia vera or post \leq essential thrombocythaemia myelofibrosis. <i>British Journal of Haematology</i> , 2017, 176, 939-949.	2.5	40
137	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. <i>Journal of Hematology and Oncology</i> , 2017, 10, 55.	17.0	302
138	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. <i>Leukemia Research</i> , 2017, 56, 52-59.	0.8	22
139	Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. <i>Lancet Haematology,the</i> , 2017, 4, e165-e175.	4.6	96
140	Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. <i>Annals of Hematology</i> , 2017, 96, 733-738.	1.8	7
141	JAK2 inhibitors for myeloproliferative neoplasms: what is next?. <i>Blood</i> , 2017, 130, 115-125.	1.4	86
142	Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 479-487.	0.4	21
143	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. <i>Haematologica</i> , 2017, 102, 94-102.	3.5	80
144	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. <i>Annals of Hematology</i> , 2017, 96, 1113-1120.	1.8	68

#	ARTICLE	IF	CITATIONS
145	Investigational Janus kinase inhibitors in development for myelofibrosis. Expert Opinion on Investigational Drugs, 2017, 26, 723-734.	4.1	10
146	A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leukemia Research, 2017, 60, 11-17.	0.8	35
147	Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. Leukemia Research, 2017, 59, 105-109.	0.8	21
148	The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leukemia Research, 2017, 58, 14-22.	0.8	30
149	Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leukemia Research, 2017, 57, 85-88.	0.8	2
150	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	1.4	214
151	An accurate, simple prognostic model consisting of age, <i>JAK2</i> , <i>CALR</i> , and <i>MPL</i> mutation status for patients with primary myelofibrosis. Haematologica, 2017, 102, 79-84.	3.5	30
152	Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. British Journal of Haematology, 2017, 176, 352-364.	2.5	23
153	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 2017, 130, 1768-1771.	1.4	52
154	A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leukemia Research, 2017, 61, 89-95.	0.8	38
155	Therapy of Myelofibrosis: Where We Are and What Next. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S93-S95.	0.4	0
156	The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Annals of Hematology, 2017, 96, 1595-1604.	1.8	38
157	Immunotherapy based approaches in myelofibrosis. Expert Review of Hematology, 2017, 10, 903-914.	2.2	12
158	JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis. Leukemia Research, 2017, 63, 53-55.	0.8	0
159	Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood, 2017, 130, 1125-1131.	1.4	180
160	Primary autoimmune myelofibrosis: a case report and review of the literature. International Journal of Hematology, 2017, 105, 536-539.	1.6	14
161	The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). British Journal of Haematology, 2017, 176, 76-85.	2.5	69
162	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia, 2017, 31, 678-687.	7.2	77

#	ARTICLE	IF	CITATIONS
163	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. <i>Journal of Hematology and Oncology</i> , 2017, 10, 156.	17.0	210
164	Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. <i>Leukemia Research</i> , 2017, 59, 110-116.	0.8	53
165	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7001-7001.	1.6	14
166	Targeting cistrome and dysregulated transcriptome of post-MPN sAML. <i>Oncotarget</i> , 2017, 8, 93301-93302.	1.8	5
167	Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. <i>Journal of Experimental Pharmacology</i> , 2016, Volume 8, 11-19.	3.2	83
168	The evolution and clinical relevance of prognostic classification systems in myelofibrosis. <i>Cancer</i> , 2016, 122, 681-692.	4.1	17
169	Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. <i>Journal of Hematology and Oncology</i> , 2016, 9, 137.	17.0	65
170	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829.	3.5	140
171	Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1572-1611.	4.9	61
172	The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. <i>Haematologica</i> , 2016, 101, e482-e484.	3.5	50
173	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
174	Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. <i>Blood</i> , 2016, 128, 877-880.	1.4	6
175	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016, 101, 1133-1143.	3.5	60
176	Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. <i>Journal of Experimental Medicine</i> , 2016, 213, 1723-1740.	8.5	128
177	Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. <i>European Journal of Haematology</i> , 2016, 97, 192-200.	2.2	46
178	Ruxolitinib dose management as a key to long-term treatment success. <i>International Journal of Hematology</i> , 2016, 104, 420-429.	1.6	10
179	Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. <i>Leukemia Research</i> , 2016, 48, 1-5.	0.8	17
180	Myelofibrosis: an update on drug therapy in 2016. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2375-2389.	1.8	9

#	ARTICLE	IF	CITATIONS
181	Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opinion on Investigational Drugs, 2016, 25, 1393-1403.	4.1	25
182	Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica, 2016, 101, 660-671.	3.5	120
183	Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemotherapy and Pharmacology, 2016, 77, 1125-1142.	2.3	36
184	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biology of Blood and Marrow Transplantation, 2016, 22, 432-440.	2.0	127
185	Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leukemia and Lymphoma, 2016, 57, 1054-1059.	1.3	18
186	Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera – single center experience. Leukemia and Lymphoma, 2016, 57, 237-239.	1.3	28
187	Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF). Blood, 2016, 128, 1936-1936.	1.4	16
188	Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Blood, 2016, 128, 478-478.	1.4	22
189	Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts $\leq 100,000/\mu\text{l}$. Blood, 2016, 128, LBA-5-LBA-5.	1.4	29
190	JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood, 2015, 125, 3352-3353.	1.4	41
191	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood, 2015, 126, 790-797.	1.4	162
192	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood, 2015, 126, 1551-1554.	1.4	151
193	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 2015, 100, 479-488.	3.5	246
194	Ruxolitinib for the treatment of patients with polycythemia vera. Expert Review of Hematology, 2015, 8, 391-401.	2.2	10
195	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	3.5	203
196	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. New England Journal of Medicine, 2015, 372, 426-435.	27.0	720
197	Novel and emerging therapies for the treatment of polycythemia vera. Expert Review of Hematology, 2015, 8, 101-113.	2.2	6
198	Eosinophilia in Hematologic Disorders. Immunology and Allergy Clinics of North America, 2015, 35, 439-452.	1.9	23

#	ARTICLE	IF	CITATIONS
199	Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2092-2097.	1.3	51
200	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leukemia Research</i> , 2015, 39, 950-956.	0.8	69
201	Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. <i>Leukemia Research</i> , 2015, 39, 419-423.	0.8	9
202	Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. <i>BMC Nephrology</i> , 2015, 16, 121.	1.8	11
203	New Therapeutic Approaches in Polycythemia Vera. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S27-S33.	0.4	11
204	Mechanisms of thrombogenesis in polycythemia vera. <i>Blood Reviews</i> , 2015, 29, 215-221.	5.7	67
205	Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. <i>Haematologica</i> , 2015, 100, 1058-63.	3.5	46
206	Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. <i>Leukemia Research</i> , 2015, 39, 822-827.	0.8	21
207	A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 171-176.	0.4	67
208	The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies. <i>Blood</i> , 2015, 126, 1604-1604.	1.4	2
209	A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET) Tj ETQq1 1104784314rgBT /Ore		
210	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. <i>Blood</i> , 2015, 126, 56-56.	1.4	28
211	Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. <i>Anticancer Research</i> , 2015, 35, 5219-23.	1.1	3
212	Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. <i>International Journal of General Medicine</i> , 2014, 7, 89.	1.8	53
213	Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. <i>Leukemia and Lymphoma</i> , 2014, 55, 5-6.	1.3	4
214	Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2215-2216.	1.3	5
215	Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E5401-10.	7.1	238
216	Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. <i>Leukemia and Lymphoma</i> , 2014, 55, 2685-2690.	1.3	24

#	ARTICLE	IF	CITATIONS
217	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. <i>Cancer</i> , 2014, 120, 513-520.	4.1	165
218	Comorbidities predict worse prognosis in patients with primary myelofibrosis. <i>Cancer</i> , 2014, 120, 2996-3002.	4.1	31
219	Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. <i>Leukemia Research</i> , 2014, 38, 316-322.	0.8	42
220	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2014, 123, 2645-2651.	1.4	192
221	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. <i>Leukemia Research</i> , 2014, 38, 1126-1129.	0.8	29
222	Preface. Best Practice and Research in Clinical Haematology, 2014, 27, 81-82.	1.7	0
223	Clinical significance of microcytosis in patients with primary myelofibrosis. <i>Leukemia Research</i> , 2014, 38, 1212-1216.	0.8	7
224	Efficacy of ruxolitinib for myelofibrosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1465-1473.	1.8	10
225	Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. <i>Leukemia Research</i> , 2014, 38, 91-94.	0.8	3
226	Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. <i>Leukemia and Lymphoma</i> , 2014, 55, 121-127.	1.3	49
227	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> , 2014, 99, 292-298.	3.5	38
228	Changing myelofibrosis's natural course at last. <i>Blood</i> , 2014, 123, 1776-1777.	1.4	5
229	Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea. <i>Blood</i> , 2014, 124, 1847-1847.	1.4	14
230	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. <i>Blood</i> , 2014, 124, 713-713.	1.4	31
231	Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. <i>Leukemia Research</i> , 2013, 37, 1472-1476.	0.8	5
232	Practical management of patients with myelofibrosis receiving ruxolitinib. <i>Expert Review of Hematology</i> , 2013, 6, 511-523.	2.2	31
233	Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chromosomal abnormalities in <sc>SM</sc> and <sc>AHNMD</sc> components. <i>American Journal of Hematology</i> , 2013, 88, 219-224.	4.1	76
234	Pharmacotherapy of polycythemia vera. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 977-985.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013, 122, 1395-1398.	1.4	286
236	TP53 mutation is rare in primary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 1552-1552.	1.3	5
237	Advanced systemic mastocytosis: the impact of <sc>KIT</sc> mutations in diagnosis, treatment, and progression. <i>European Journal of Haematology</i> , 2013, 90, 89-98.	2.2	48
238	Chromosome 5q deletion is extremely rare in patients with myelofibrosis. <i>Leukemia Research</i> , 2013, 37, 552-555.	0.8	9
239	Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 1933-1940.	7.0	246
240	Investigational Janus kinase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 687-699.	4.1	44
241	Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 2537-2539.	1.3	18
242	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase <sc>III</sc> study in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2013, 161, 508-516.	2.5	83
243	Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 577-588.	4.1	94
244	Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis. <i>Postgraduate Medicine</i> , 2013, 125, 128-135.	2.0	45
245	Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. <i>Journal of Hematology and Oncology</i> , 2013, 6, 81.	17.0	89
246	Significance of cytogenetic abnormalities in patients with polycythemia vera. <i>Leukemia and Lymphoma</i> , 2013, 54, 2667-2670.	1.3	21
247	Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 1959-1964.	1.3	7
248	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	1.4	122
249	Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. <i>Haematologica</i> , 2013, 98, 1865-1871.	3.5	143
250	Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. <i>OncoTargets and Therapy</i> , 2013, 7, 13.	2.0	46
251	Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts $\leq 100,000/\mu\text{l}$. <i>Blood</i> , 2013, 122, 395-395.	1.4	16
252	Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 1424-1424.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Emerging drugs for myelofibrosis. Expert Opinion on Emerging Drugs, 2012, 17, 555-570.	2.4	4
254	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, 2012, 120, 1202-1209.	1.4	205
255	Breakthroughs in myeloproliferative neoplasms. Hematology, 2012, 17, s55-s58.	1.5	6
256	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine, 2012, 366, 799-807.	27.0	1,738
257	Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leukemia Research, 2012, 36, 1124-1127.	0.8	65
258	Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Review of Hematology, 2012, 5, 631-641.	2.2	3
259	Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2012, 26, 1083-1099.	2.2	16
260	Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature, 2012, 489, 155-159.	27.8	320
261	Ruxolitinib: the first agent approved for myelofibrosis. Clinical Advances in Hematology and Oncology, 2012, 10, 111-3.	0.3	3
262	New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opinion on Investigational Drugs, 2011, 20, 961-972.	4.1	20
263	Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood, 2011, 118, 899-902.	1.4	55
264	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Reviews Drug Discovery, 2011, 10, 127-140.	46.4	261
265	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	1.6	724
266	Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Investigational New Drugs, 2011, 29, 818-826.	2.6	22
267	Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. Cancer, 2011, 117, 4869-4877.	4.1	50
268	Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer, 2011, 117, 5439-5449.	4.1	25
269	JAK2 inhibitors: What's the true therapeutic potential?. Blood Reviews, 2011, 25, 53-63.	5.7	65
270	Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells. Clinical Cancer Research, 2011, 17, 7347-7358.	7.0	90

#	ARTICLE	IF	CITATIONS
271	MER1, a novel organic arsenic derivative, has potent PML-RAR α - independent cytotoxic activity against leukemia cells. <i>Investigational New Drugs</i> , 2010, 28, 402-412.	2.6	12
272	Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis. <i>Clinical Cancer Research</i> , 2010, 16, 1988-1996.	7.0	39
273	Treatment of aggressive systemic mastocytosis with daclizumab. <i>Leukemia and Lymphoma</i> , 2010, 51, 540-542.	1.3	8
274	Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. <i>Leukemia and Lymphoma</i> , 2010, 51, 269-274.	1.3	18
275	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 555-559.	2.0	46
276	Safety and Efficacy of INCBO18424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. <i>New England Journal of Medicine</i> , 2010, 363, 1117-1127.	27.0	1,046
277	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 4563-4569.	1.6	213
278	Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 4760-4766.	1.6	152
279	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 663-670.	2.4	28
280	Effective Treatment of Acute Promyelocytic Leukemia With All- <i>Trans</i> -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. <i>Journal of Clinical Oncology</i> , 2009, 27, 504-510.	1.6	355
281	Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post- α -Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 5587-5593.	1.6	117
282	Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. <i>Journal of Clinical Oncology</i> , 2009, 27, 5418-5424.	1.6	367
283	Treatment of myelofibrosis in younger patients: To transplant or not?. <i>American Journal of Hematology</i> , 2009, 84, 131-132.	4.1	1
284	Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. <i>International Journal of Hematology</i> , 2009, 90, 58-63.	1.6	12
285	Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. <i>International Journal of Hematology</i> , 2009, 90, 522-525.	1.6	12
286	Pregnancy in a patient with hypereosinophilic syndrome. <i>Leukemia Research</i> , 2009, 33, 186-187.	0.8	7
287	Preclinical and clinical experience with dasatinib in philadelphia chromosome-negative leukemias and myeloid disorders. <i>Leukemia Research</i> , 2009, 33, 617-623.	0.8	8
288	Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. <i>Leukemia Research</i> , 2009, 33, 1481-1484.	0.8	146

#	ARTICLE	IF	CITATIONS
289	The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. <i>Leukemia Research</i> , 2009, 33, 1199-1203.	0.8	203
290	Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient. <i>Leukemia Research</i> , 2009, 33, e186-e188.	0.8	3
291	Therapeutic potential of JAK2 inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 636-642.	2.5	93
292	Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 368-373.	7.0	67
293	Granulocytic sarcoma with massive scalp involvement. <i>American Journal of Hematology</i> , 2008, 83, 340-342.	4.1	1
294	The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2 ^{V617F} mutation. <i>Cancer Science</i> , 2008, 99, 1265-1273.	3.9	57
295	The natural history and treatment outcome of blast phase BCR-ABL ⁻ myeloproliferative neoplasms. <i>Blood</i> , 2008, 112, 1628-1637.	1.4	152
296	Phase II Study of Dasatinib in Philadelphia Chromosome ⁻ Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. <i>Clinical Cancer Research</i> , 2008, 14, 3906-3915.	7.0	151
297	EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. <i>Blood</i> , 2007, 109, 315-322.	1.4	69
298	Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?. <i>Leukemia and Lymphoma</i> , 2007, 48, 445-446.	1.3	1
299	Treatment of systemic mastocytosis with denileukin diftitox. <i>American Journal of Hematology</i> , 2007, 82, 1124-1124.	4.1	9
300	A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. <i>Cancer</i> , 2007, 110, 955-964.	4.1	30
301	PEG-IFN- α -2b therapy in BCR-ABL ⁻ negative myeloproliferative disorders. <i>Cancer</i> , 2007, 110, 2012-2018.	4.1	107
302	Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. <i>Cancer Science</i> , 2007, 98, 1223-1225.	3.9	16
303	Experimental therapy in myelofibrosis with myeloid metaplasia. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1555-1563.	4.1	4
304	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood</i> , 2006, 107, 3469-3473.	1.4	371
305	Lenalidomide therapy in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2006, 108, 1158-1164.	1.4	239
306	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006, 108, 1497-1503.	1.4	317

#	ARTICLE	IF	CITATIONS
307	Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR- $\hat{\pm}$ -expressing cells. <i>Leukemia Research</i> , 2006, 30, 1499-1505.	0.8	32
308	Staging of chronic myeloid leukemia in the imatinib era. <i>Cancer</i> , 2006, 106, 1306-1315.	4.1	107
309	Thalidomide therapy for myelofibrosis with myeloid metaplasia. <i>Cancer</i> , 2006, 106, 1974-1984.	4.1	90
310	Novel approaches in the treatment of systemic mastocytosis. <i>Cancer</i> , 2006, 107, 1429-1439.	4.1	63
311	Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?. <i>Hematological Oncology</i> , 2006, 24, 181-188.	1.7	47
312	Pegylated Interferon Therapy for Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 409-416.	2.7	20
313	Advances in the Therapy of Chronic Idiopathic Myelofibrosis. <i>Oncologist</i> , 2006, 11, 929-943.	3.7	31
314	New approaches in the treatment of myelofibrosis. <i>Cancer</i> , 2005, 103, 32-43.	4.1	20
315	Interferon $\hat{\pm}$ therapy for patients with essential thrombocythemia. <i>Cancer</i> , 2005, 103, 2551-2557.	4.1	21
316	Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience. <i>American Journal of Hematology</i> , 2004, 77, 209-214.	4.1	47
317	Arsenic derivatives as therapeutic agents for hematologic malignancies. <i>Leukemia Research</i> , 2004, 28, 901-903.	0.8	9
318	Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 81-86.	2.3	43
319	In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 427-432.	2.3	20
320	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. <i>Modern Pathology</i> , 0, , .	5.5	0